Search
MapLight Therapeutics Inc
MPLTAdd to Watchlist
36.137USD
+0.057+0.16%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.63BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated:Analyst Rating
Based on
11
analysts
Buy
Current Rating
38.900
Target Price
+8.54%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
MapLight Therapeutics Inc
MPLT
11
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is the analyst rating for MapLight Therapeutics Inc?
Based on the ratings of MapLight Therapeutics Inc's stock from 11 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.